Jan Stoehlmacher

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · The Lancet · 2019 · 2.4K citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +9

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein et al. · The Lancet Oncology · 2009 · 953 citations

Hepatology, Gastrointestinal Oncology, Medicine +8

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

Salah‐Eddin Al‐Batran, J. T. Hartmann, Stephan Probst et al. · Journal of Clinical Oncology · 2008 · 778 citations · Full text

<i>ERCC1</i> and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy

Yoshinori Shirota, Jan Stoehlmacher, Jan Brabender et al. · Journal of Clinical Oncology · 2001 · 607 citations

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

Sheeja T. Pullarkat, Jan Stoehlmacher, Viviane S. Ghaderi et al. · The Pharmacogenomics Journal · 2001 · 572 citations

Oncogenic Agent, 5-Fu Chemotherapy, Medicine +6